Altay Therapeutics
Altay Therapeutics, based in California, specializes in developing small molecule drugs for chronic liver diseases, including liver fibrosis and liver cancer, aiming to impact a market of over 20 million Americans.
Company History
Altay Therapeutics, previously known as Altay Therapeutics Inc, was formed as part of the W20 batch of Y-Combinator. The company operates from locations in San Carlos, CA, and South San Francisco, CA. Its team comprises of six members who collectively have over 70 years of experience in small molecule drug development. Altay Therapeutics develops small molecule drugs specifically aimed at treating chronic liver diseases such as liver fibrosis and liver cancer.
Services
Altay Therapeutics focuses on the development of small molecule drugs designed to treat chronic liver diseases. One of their main therapeutic goals is to combat liver fibrosis and liver cancer. Their small molecule drugs are currently validated through pre-clinical models, demonstrating significant efficacy in reducing fibrosis and potentially reversing fibrotic tissue back to normal.
Founders
Altay Therapeutics was co-founded by Dr. Osman Ozes, who has significant experience in the field of drug development. Dr. Ozes previously led the first drug development program for Esbriet (Pirfenidone), which became the first FDA-approved therapy for lung fibrosis. His expertise significantly contributes to Altay Therapeutics' mission and strategic direction.
Industry and Market
Altay Therapeutics operates within the healthcare industry, specifically the therapeutics sub-industry. The company aims to address chronic liver diseases, which impact over 20 million Americans and represent a market size of over $30 billion. Their innovative small molecule drugs offer a promising treatment option for diseases that currently have limited therapies.
Research and Development
Altay Therapeutics has demonstrated excellent pre-clinical results in several mouse models of liver fibrosis. Their novel small molecule drugs have shown positive outcomes, including the reduction in fibrosis and the potential reversal of fibrotic tissue back to normal. The company aims to have a clinic-ready compound by the end of 2021 and to enter phase I clinical trials by mid-2022. This development showcases their commitment to advancing therapeutic options for chronic liver diseases.
